Company to Initiate Investigational Cardiovascular Study with Dr. Azimi and NanoStilbene
OCEANSIDE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc.,
(OTC Markets:TSOI) announced today that Nassir Azimi, M.D., has been appointed to the Company's Scientific Advisory Board. In
addition to this, Dr. Azimi plans to work with the Company to investigate the use of its product NanoStilbene in heart attack
victims.
Dr. Azimi attended Dartmouth Medical School and completed his residency at the University of Colorado. He finished his four-year
fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr. Azimi has been in private practice
for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating patients for peripheral
vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director of La Mesa
Cardiac Center's Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for various
cardiac and peripheral diseases.
Cardiovascular disease and cancer are the largest contributors to the burden of chronic disease in the United States. With an
estimated 15 million Americans with heart disease and 14 million with a history of cancer, these numbers will undoubtedly rise as
the population grows older and therapies enhance longevity.
"Our Scientific Team at TSOI proudly welcomes Dr. Azimi in joining us today and we are very excited about the expertise he
brings to our work. Inflammation is a unifying theme among a variety of diseases, including both cardiovascular disease and cancer.
Accumulating evidence suggests that oxidative stress and its direct consequences, including lipid peroxidation, are involved in
numerous pathological states including atherosclerosis, cancer, and inflammation," said Timothy Dixon, President, and CEO. "Dr.
Azimi is a big proponent on the uses of antioxidants such as our nanoparticle pterostilbene product NanoStilbene, in cardiovascular
patients, a product included in two of our cancer vaccines in use at the Pan Am Cancer Treatment Center in Tijuana, Mexico we
recently announced."
"I envision a world where NanoStilbene is an essential adjunct to standard medical treatment in patients with cancer and heart
disease. Cardiovascular disease is a leading cause of death in the United States as well as worldwide. With improvements and
developments of new novel therapies for patients with cardiovascular disease remains a primary research goal of many clinicians and
researchers. Apoptosis, necrosis, and autophagy occur in cardiac myocytes (the muscle cells (myocytes) that make up the cardiac
muscle (heart muscle), and both gradual and acute cell death are hallmarks of cardiac pathology, including heart failure,
myocardial infarction, and ischemia/reperfusion," said Dr. Azimi. "By supplementing NanoStilbene in heart attack patients, we hope
to show a reduction in apoptosis of cardiomyocytes," added Dr. Azimi.
"It is my honor to work together with Dr. Azimi, a seasoned veteran in the area of cardiovascular therapeutics, in developing
interventions that address the current unmet medical need of post-infarct cardiac repair," said Dr. Hong Ma, the Company's Chief
Scientific Officer. "Given the excellent track record of the pterostilbene molecule in modulating numerous inflammatory and
regenerative processes, we are enthusiastic to rapidly translate animal studies into the clinical arena."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system.
The Company's corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press
release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future
events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
